7,682 Shares in HCA Healthcare, Inc. $HCA Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new position in shares of HCA Healthcare, Inc. (NYSE:HCA) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,682 shares of the company’s stock, valued at approximately $2,943,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in HCA Healthcare by 83.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock valued at $829,104,000 after purchasing an additional 1,091,416 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in HCA Healthcare by 49.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock valued at $615,583,000 after purchasing an additional 587,036 shares during the last quarter. Nuveen LLC acquired a new stake in HCA Healthcare in the first quarter valued at $569,217,000. Pacer Advisors Inc. grew its holdings in HCA Healthcare by 6,237.9% in the first quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock valued at $466,815,000 after purchasing an additional 1,329,618 shares during the last quarter. Finally, Nordea Investment Management AB grew its holdings in HCA Healthcare by 6.8% in the second quarter. Nordea Investment Management AB now owns 927,781 shares of the company’s stock valued at $350,404,000 after purchasing an additional 59,163 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Trading Down 0.4%

NYSE HCA opened at $466.44 on Friday. The business’s 50-day moving average price is $420.00 and its 200 day moving average price is $385.66. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $478.19. The company has a market capitalization of $109.14 billion, a PE ratio of 18.03, a price-to-earnings-growth ratio of 1.38 and a beta of 1.40.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings data on Friday, October 24th. The company reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $1.32. The company had revenue of $19.16 billion for the quarter, compared to the consensus estimate of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the business posted $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. Equities analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 29th. Stockholders of record on Monday, December 15th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, December 15th. HCA Healthcare’s dividend payout ratio (DPR) is 11.13%.

Insider Activity

In other news, EVP Michael S. Cuffe sold 3,836 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the sale, the executive vice president owned 31,503 shares in the company, valued at approximately $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

HCA has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of HCA Healthcare in a research note on Wednesday, October 8th. Barclays increased their price objective on HCA Healthcare from $445.00 to $494.00 and gave the company an “overweight” rating in a research note on Monday. Royal Bank Of Canada increased their price objective on HCA Healthcare from $449.00 to $482.00 and gave the company an “outperform” rating in a research note on Monday. Stephens increased their price objective on HCA Healthcare from $450.00 to $500.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Morgan Stanley set a $425.00 price objective on HCA Healthcare in a research note on Monday. Fourteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $473.53.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.